Ultragenyx Pharmaceutical (RARE) Non Operating Investment Income (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Non Operating Investment Income data on file, last reported at $678000.0 in Q3 2025.

• On a quarterly basis, Non Operating Investment Income changed 0.0% year-over-year to $678000.0 in Q3 2025; TTM through Sep 2025 was -$1.0 million, a 144.62% decrease from a year earlier, with the FY2024 full-year figure at -$1.1 million, down 380.86% from the prior year.
• Non Operating Investment Income for Q3 2025 stood at $678000.0, up from -$9000.0 in the prior quarter.
• Over the last five years, Non Operating Investment Income for RARE reached as high as $25.7 million in Q3 2021 and fell as low as -$31.0 million in Q2 2021.
• Historically, Non Operating Investment Income has averaged -$3.2 million across 5 years, with a median of -$334000.0 in 2023.
• On a YoY basis, Non Operating Investment Income climbed as much as 1221.56% in 2024 and fell as far as 1629.12% in 2024.
• Year by year, Non Operating Investment Income stood at -$16.1 million in 2021, then jumped by 111.43% to $1.8 million in 2022, then increased by 2.66% to $1.9 million in 2023, then tumbled by 181.95% to -$1.5 million in 2024, then soared by 143.8% to $678000.0 in 2025.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were $678000.0 in Q3 2025, -$9000.0 in Q2 2025, and -$157000.0 in Q1 2025.